Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

Nature Medicine volume 10, pages 48–54 (2004)Cite this article

A Corrigendum to this article was published on 01 February 2004

Abstract

Although tumor progression involves processes such as tissue invasion that can activate inflammatory responses, the immune system largely ignores or tolerates disseminated cancers. The mechanisms that block initiation of immune responses during cancer development are poorly understood. We report here that constitutive activation of Stat-3, a common oncogenic signaling pathway, suppresses tumor expression of proinflammatory mediators. Blocking Stat-3 in tumor cells increases expression of proinflammatory cytokines and chemokines that activate innate immunity and dendritic cells, leading to tumor-specific T-cell responses. In addition, constitutive Stat-3 activity induces production of pleiotropic factors that inhibit dendritic cell functional maturation. Tumor-derived factors inhibit dendritic cell maturation through Stat-3 activation in progenitor cells. Thus, inhibition of antitumor immunity involves a cascade of Stat-3 activation propagating from tumor to dendritic cells. We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Blocking Stat-3 in tumor cells increases proinflammatory cytokine and chemokine expression.
Figure 2: Constitutive Stat-3 activity inhibits cytokine and chemokine gene expression.
Figure 3: Blocking Stat-3 in tumor cells stimulates macrophages and neutrophils.
Figure 4: Stat-3-interrupted tumor cells activated dendritic cells and naive antigen-specific T cells.
Figure 5: Stat-3 signaling induces expression of factors that inhibit dendritic cell maturation.
Figure 6: Stat-3 signaling mediates inhibition of dendritic cell maturation.

References

  1. Kaplan, D.H. et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556–7561 (1998).

    CAS  Google Scholar 

  2. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).

    Article  CAS  Google Scholar 

  3. Fuchs, E.J. & Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol. 8, 271–280 (1996).

    Article  CAS  Google Scholar 

  4. Pardoll, D.M. Cancer vaccines. Nat. Med. 4, 525–531 (1998).

    Article  CAS  Google Scholar 

  5. Steinman, R.M. & Nussenzweig, M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351–358 (2002).

    Article  CAS  Google Scholar 

  6. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).

    Article  CAS  Google Scholar 

  7. Gabrilovich, D.I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096–1103 (1996).

    Article  CAS  Google Scholar 

  8. Sombroek, C.C. et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168, 4333–4343 (2002).

    Article  CAS  Google Scholar 

  9. Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39–49 (1999).

    Article  CAS  Google Scholar 

  10. Cheng, F. et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425–436 (2003).

    Article  CAS  Google Scholar 

  11. Bromberg, J.F. et al. Stat3 as an oncogene. Cell 98, 295–303 (1999).

    Article  CAS  Google Scholar 

  12. Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105–115 (1999).

    Article  CAS  Google Scholar 

  13. Bowman, T. et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98, 7319–7324 (2001).

    Article  CAS  Google Scholar 

  14. Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000–2008 (2002).

    Article  CAS  Google Scholar 

  15. Bowman, T., Garcia, R., Turkson, J. & Jove, R. STATs in oncogenesis. Oncogene 19, 2474–2488 (2000).

    Article  CAS  Google Scholar 

  16. Niu, G. et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59, 5059–5063 (1999).

    CAS  PubMed  Google Scholar 

  17. Niu, G. et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 61, 3276–3280 (2001).

    CAS  PubMed  Google Scholar 

  18. Janeway, C.A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1–13 (1989).

    Article  CAS  Google Scholar 

  19. Fearon, D.T. & Locksley, R.M. The instructive role of innate immunity in the acquired immune response. Science 272, 50–54 (1996).

    Article  CAS  Google Scholar 

  20. Medzhitov, R. & Janeway, J.C.A. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9, 4–9 (1997).

    Article  CAS  Google Scholar 

  21. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249–1255 (1999).

    Article  CAS  Google Scholar 

  22. Mellman, I. & Steinman, R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255–258 (2001).

    Article  CAS  Google Scholar 

  23. Bloom, M.B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453–459 (1997).

    Article  CAS  Google Scholar 

  24. Slansky, J.E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13, 529–538 (2000).

    Article  CAS  Google Scholar 

  25. McLemore, M.L. et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14, 193–204 (2001).

    Article  CAS  Google Scholar 

  26. Brossart, P. et al. Tumor necrosis factor α and CD40 ligand antagonize the inhibitory effect of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 60, 4485–4492 (2000).

    CAS  PubMed  Google Scholar 

  27. Weber-Nordt, R.M. et al. Stat3 recruitment by two distinct ligand-induced, tyrosine- phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271, 27954–27961 (1996).

    Article  CAS  Google Scholar 

  28. Bartoli, M. et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 17, 1562–1564 (2003).

    Article  CAS  Google Scholar 

  29. Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem. 276, 45443–45455 (2001).

    Article  CAS  Google Scholar 

  30. Davidson, J.M. Wound repair. in Inflammation (ed. J.L. Gallin) 809–819 (Garland Press, New York, 1992).

    Google Scholar 

  31. Sano, S. et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18, 4657–4668 (1999).

    Article  CAS  Google Scholar 

  32. Urban, J.L., Burton, R.C., Holand, J.M., Kripke, M.L. & Schreiber, H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 155, 557–573 (1982).

    Article  CAS  Google Scholar 

  33. Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040–1052 (1983).

    Article  CAS  Google Scholar 

  34. Wortzel, R.D., Philipps, C. & Schreiber, H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304, 165–167 (1983).

    Article  CAS  Google Scholar 

  35. Ochsenbein, A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058–1064 (2001).

    Article  CAS  Google Scholar 

  36. Lee, C.K. et al. Stat3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17, 63–72 (2002).

    Article  CAS  Google Scholar 

  37. Turkson, J. et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol. 18, 2545–2552 (1998).

    Article  CAS  Google Scholar 

  38. Lu, Z. et al. CD-40-independent pathways of T cell help for priming of CD8+ cytotoxic T lymphocytes. J. Exp. Med. 191, 541–550 (2000).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank S. Akira and K. Takeda for Stat3flox mice, D. Link for the Stat-3C and Stat-3D retrovirus–producing cell lines, J. Bromberg for the Stat-3C plasmid and H. von Boehmer for CD4+ TCR transgenic mice. This work is supported by US National Institutes of Health grants, by the Dr. Tsai-fan Yu Cancer Research Endowment and by gifts from Mrs. Dorothy Needle, William and Betty Topercer, Jack Goldsmith, the Janey Fund and the Seraph Foundation.

Author information

Author notes

  1. Tianhong Wang, Guilian Niu, Marcin Kortylewski and Lyudmila Burdelya: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, 21205, Maryland, USA

    Tianhong Wang & Drew Pardoll

  2. Department of Interdisciplinary Oncology, Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, 33612, Florida, USA

    Guilian Niu, Marcin Kortylewski, Lyudmila Burdelya, Raka Bhattacharya, Dmitry Gabrilovich & Hua Yu

  3. Department of Interdisciplinary Oncology, Clinical Investigations Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, 33612, Florida, USA

    Kenneth Shain, Richard Heller, Domenico Coppola & William Dalton

  4. Department of Interdisciplinary Oncology, Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, 33612, Florida, USA

    Shumin Zhang & Richard Jove

Authors
  1. Tianhong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guilian Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcin Kortylewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lyudmila Burdelya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth Shain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shumin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raka Bhattacharya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dmitry Gabrilovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Richard Heller
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Domenico Coppola
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. William Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Richard Jove
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Drew Pardoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hua Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Drew Pardoll or Hua Yu.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wang, T., Niu, G., Kortylewski, M. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10, 48–54 (2004). https://doi.org/10.1038/nm976

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm976

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing